Monoclonal antibodies against macrophage colony-stimulating factor diminish the number of circulating intermediate and nonclassical (CD14(++)CD16(+)/CD14(+)CD16(++)) monocytes in rheumatoid arthritis patient

Blood. 2012 May 31;119(22):5329-30. doi: 10.1182/blood-2012-02-412551.
No abstract available

Publication types

  • Clinical Trial, Phase I
  • Letter

MeSH terms

  • Adult
  • Antibodies, Monoclonal / administration & dosage*
  • Antibodies, Monoclonal / immunology
  • Arthritis, Rheumatoid / blood*
  • Arthritis, Rheumatoid / drug therapy
  • Arthritis, Rheumatoid / immunology
  • Double-Blind Method
  • Female
  • GPI-Linked Proteins / blood
  • GPI-Linked Proteins / immunology
  • Humans
  • Lipopolysaccharide Receptors / blood*
  • Lipopolysaccharide Receptors / immunology
  • Macrophage Colony-Stimulating Factor / antagonists & inhibitors*
  • Macrophage Colony-Stimulating Factor / blood
  • Macrophage Colony-Stimulating Factor / immunology
  • Male
  • Monocytes / immunology
  • Monocytes / metabolism*
  • Receptors, IgG / blood*
  • Receptors, IgG / immunology

Substances

  • Antibodies, Monoclonal
  • FCGR3B protein, human
  • GPI-Linked Proteins
  • Lipopolysaccharide Receptors
  • Receptors, IgG
  • Macrophage Colony-Stimulating Factor